2 mg nicotine gum + 4 mg nicotine gum

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Dental Pellicle

Conditions

Dental Pellicle

Trial Timeline

Jul 1, 2005 โ†’ Sep 1, 2005

About 2 mg nicotine gum + 4 mg nicotine gum

2 mg nicotine gum + 4 mg nicotine gum is a approved stage product being developed by Johnson & Johnson for Dental Pellicle. The current trial status is completed. This product is registered under clinical trial identifier NCT00174499. Target conditions include Dental Pellicle.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00174499ApprovedCompleted

Competing Products

20 competing products in Dental Pellicle

See all competitors
ProductCompanyStageHype Score
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
77
Sodium Fluoride DentifriceJohnson & JohnsonPre-clinical
23
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
77
Acetaminophen (ACE) (1000 mg) + Commercial ACE (1000 mg) + Commercial Ibuprofen (IBU) (400 mg) + Placebo + Placebo + PlaceboJohnson & JohnsonPhase 2
52
Acetaminophen ER + PlaceboJohnson & JohnsonPhase 2
52
acetaminophen Tablet + acetaminophen Caplet + ibuprofen Liquid-filled capsule + Placebo Tablet + Placebo Caplet + Placebo Liquid-filled capsuleJohnson & JohnsonPhase 3
77
Diclofenac potassium + Ibuprofen + Placebo to ibuprofen + Placebo to diclofenac potassiumNovartisPhase 3
77
Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oral + ARRY-371797, p38 inhibitor; oral + Celecoxib, COX-2 inhibitor; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oralPfizerPhase 2
51
Pregabalin + Alprazolam + PlaceboPfizerPhase 2
51
Prototype (AN0128 Toothpaste)PfizerPhase 1
32
PF-05089771 + PF-05089771 + PF-05089771 + IbuprofenPfizerPhase 2
51
ARRY-371797, p38 inhibitor; oral + Placebo; oral + Placebo; oral + ARRY-371797, p38 inhibitor; oralPfizerPhase 2
51
PF-04531083 + PF-04531083 + IbuprofenPfizerPhase 2
51
Naproxen sodium and caffeine (BAY2880376) + Naproxen sodium (Aleve) + Caffeine + PlaceboBayerPhase 3
74
XPF-001 + placeboXenon PharmaceuticalsPhase 2
49
N1539 + placebo + N1539 + N1539 + MotrinAlkermesPhase 2
49
Comparator: etoricoxib + Comparator: ibuprofen + Comparator: acetaminophen + codeine + Comparator: placeboOrganonPhase 3
72
Full Dose Strength + Quarter dose strength + Half dose strength + Acetaminophen standard dose + Ibuprofen low dose + Ibuprofen high dose + PlaceboAFT PharmaceuticalsPhase 2
44
Maxigesic 325 + Acetaminophen + Ibuprofen + PlaceboAFT PharmaceuticalsPhase 3
69
C16G2 GelArmata PharmaceuticalsPhase 2
44